FDA approval for ixekizumab for psoriasis
FDA approves ixekizumab for psoriasis. There is a hope that will compete against a new wave of rival therapies for psoriasis.
By 2020, analysts expect IL-17A anti-inflammatory drug to carve out a market worth more than a billion dollars a year. Few weeks ago, the European Medicines Agency signalled its approval for the therapy, giving way to another big market later this year.
Inflammation is triggered when ixekizumab binds to the protein interleukin (IL)-17A. Lilly aimed for a top role in the market by inculcating head-to-head late-stage studies against market leaders, plus Etanercept.
Many people living with plaque psoriasis are looking for another treatment option for this disease. With this FDA approval, this drug provides significant improvement of psoriasis plaques." As per Dr. Julie Beitz, director of the Office of Drug Evaluation III in FDA's Center for Drug Evaluation and Research, “Today’s approval provides patients suffering from plaque psoriasis with another important treatment option to help relieve the skin irritation and discomfort from the condition."